LBG
ALXN

Lloyds Banking Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Lloyds Banking Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,271
Closed -$542K – 434
2014
Q3 		$542K Sell
3,271
-382
-10% -$62.7K 0.15% 169
2014
Q2 		$570K Sell
3,653
-44,834
-92% -$7.08M 0.14% 174
2014
Q1 		$7.38M Buy
48,487
+5,591
+13% +$889K 0.07% 245
2013
Q4 		$5.71M Buy
42,896
+3,139
+8% +$377K 0.05% 280
2013
Q3 		$4.62M Buy
39,757
+2,746
+7% +$301K 0.05% 281
2013
Q2 		$3.41M Buy
+37,011
New +$3.57M 0.04% 315

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return